VBI Vaccines Inc.

Equities

VBIV

CA91822J2020

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
0.58 USD 0.00% Intraday chart for VBI Vaccines Inc. +0.87% -1.28%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
North American Morning Briefing : Tech in Focus on -2- DJ
North American Morning Briefing : Investors -2- DJ
North American Morning Briefing : Stock Futures -2- DJ
VBI Vaccines Sells Rights to Hepatitis B Vaccine to Brii Biosciences MT
VBI Vaccines Inc. Enter into New License Agreement with Brii Biosciences CI
Brii Biosciences to Buy Rights to Hepatitis B Vaccine from VBI MT
VBI Vaccines Inc. and VBI Cda Enters into a Forbearance Agreement with K2 HealthVentures LLC CI
VBI Vaccines Inc. and VBI Cda Enters into a Forbearance Agreement with K2 HealthVentures LLC CI
VBI Vaccines Inc. Along with Its Subsidiary VBI Cda Provides Update on Forbearance Agreement CI
VBI Vaccines Inc. along with its subsidiary VBI Cda and the Lenders Agrees to Extend the Forbearance Period Through and Including December 12, 2023 CI
VBI Vaccines Inc. Presents Additional Biomarker Data from Phase 1/2a Study of VBI-1901 in Recurrent GBM at the 2023 Society for Neuro-Oncology Annual Meeting CI
North American Morning Briefing : Stock Futures -2- DJ
Earnings Flash (VBIV) VBI VACCINES Posts Q3 Revenue $6.6M MT
VBI Vaccines Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
VBI Vaccines Expands Proprietary Technology Platforms With Development of a Novel mRNA-Launched eVLP Vaccine Program CI
VBI Vaccines Inc. Announces Interim Data from the Phase 1 Clinical Study of its Multivalent Pan-Coronavirus Vaccine Candidate, VBI-2901 CI
VBI Vaccines Inc. Announces Dosing of First Patients in Phase 2b Study of VBI-1901 in Recurrent GBM CI
Earnings Flash (VBIV) VBI VACCINES Reports Q2 Revenue $720,000 MT
VBI Vaccines Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
North American Morning Briefing : Stock Futures -2- DJ
North American Morning Briefing : Investors Await -2- DJ
VBI Vaccines' Hepatitis B Vaccine PreHevbri Is Available in Netherlands, Belgium; Shares Rise Midday MT
VBI Vaccines Inc. Announces PreHevbri® is Now Available in the Netherlands and Belgium for the Prevention of Hepatitis B in Adults CI
Insider Buy: VBI Vaccines Inc MT
Top Midday Decliners MT
Chart VBI Vaccines Inc.
More charts
VBI Vaccines Inc. is a commercial stage biopharmaceutical company. Through its approach to virus-like particles (VLPs), including an enveloped VLP (eVLP) platform technology, The Company develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. The Company is focused on targeting and overcoming infectious diseases, including hepatitis B (HBV), COVID-19, and coronaviruses, and cytomegalovirus (CMV), as well as cancers, including glioblastoma (GBM). Its product pipeline includes an approved vaccine and multiple late- and early-stage investigational programs. PreHevbrio is its approved vaccine for hepatitis B. Its Prophylactic Candidates for corona virus disease include VBI-2901, VBI-2905, VBI-2902, and other. VBI-1501 is its Prophylactic Candidate for cytomegalovirus. VBI-2501 is its Prophylactic Candidate for Zika virus. VBI-2601 and VBI-1901 are the therapeutic candidates for HBV and GBM.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.58 USD
Average target price
6 USD
Spread / Average Target
+934.48%
Consensus
  1. Stock
  2. Equities
  3. Stock VBI Vaccines Inc. - Nasdaq
  4. News VBI Vaccines Inc.
  5. VBI Vaccines : Initiates Enrollment in Phase 1/2 Study of COVID-19 Vaccine Candidate VBI-2902; Shares Rise Pre-Bell